Clinical studies reported that angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs) inhibit increases in urine albumin/urine protein and progression of renal dysfunction in early-stage nephropathy [7, 8]. This evidence concerns the gene ALB and kidney disorder.